Sars-Cov-2
Since November 2019, cases of lethal infection associated with a new
coronavirus, SARS-Cov-2 (COVID-19), have occurred in China, and then
rapidly in several countries around the world.. At the time of writing
this article are recorded about 3.7 million infected in the world with
about 1.25 million healed and about 265 thousand deaths. This global
pandemic has triggered a global health crisis with few precedents in
human history. From the various studies carried out, the phase of the
infection has been divided into three phases, the first with mild or
absent symptoms where the immune system fights the virus, the second
where the symptomatology is more serious and there is a hyperactive
inflammatory system, the third where the immune system is altered and
there is a generalized inflammatory state that can cause serious and
fatal lung lesions and multi-organ dysfunction. (1-2) To date, there are
no vaccines for the virus, nor direct antivirals. The drugs used are
registered antivirals for other viral infections, or drugs that act on
the generalized inflammatory state such as immunomodulants. While we are
waiting for the discovery of an effective vaccine or direct antiviral
against Sars-cov-2 soon, excellent hopes come from the passive
immunization of the infected patient with the administration of
convalescent plasma from patients already cured of the infection. The
Plasma therapy (PT) has already shown benefits in the treatment of
prophylaxis and treatment for Sars-Cov-2 infection.(3-4)